DAX23.954 -0,7%ESt505.407 -0,9%Top 10 Crypto14,95 +0,7%Dow41.775 -0,2%Nas18.971 +0,5%Bitcoin98.169 +1,4%Euro1,1291 -0,4%Öl64,32 -0,4%Gold3.300 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 D-Wave Quantum A3DSV9 BYD A0M4W9 HENSOLDT HAG000 Tesla A1CX3T Deutsche Bank 514000 Siemens Energy ENER6Y Deutsche Telekom 555750 Bayer BAY001 freenet A0Z2ZZ Infineon 623100 Lufthansa 823212 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fällt unter 24.000-Punkte-Marke -- Dow stabil -- Umsatz von Snowflake knackt die Milliarde -- Bitcoin mit neuem Rekord - Beiersdorf, Metaplanet, Evonik, Strategy, Innoscripta, Rheinmetall im Fokus
Top News
Evonik-Aktie verliert dennoch: EBITDA-Steigerung in Milliardenhöhe bis 2027 geplant Evonik-Aktie verliert dennoch: EBITDA-Steigerung in Milliardenhöhe bis 2027 geplant
Sanofi-Aktie verliert: Sanofi kauft Vigil Neuroscience Sanofi-Aktie verliert: Sanofi kauft Vigil Neuroscience
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Kreislaufwirtschaft als Investmentchance: Jetzt nachhaltig handeln, Renditechancen nutzen und Portfolio zukunftssicher aufstellen!

Novo Nordisk (spons. ADRs) Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
59,90 EUR +0,10 EUR +0,17 %
FSE
67,33 USD -0,85 USD -1,25 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone
KGV26,16Div. Rendite1,37%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN866931

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6701002056

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNVO

Novo Nordisk (spons. ADRs) Aktien News

DatumMeistgelesen
PR NewswireNovo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
Wer­bungNovo Nordisk (spons. ADRs)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireLevi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
PR NewswireNovo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
PR NewswireLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
PR NewswireNovo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO
PR NewswireInvestors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Lawsuit - NVO
PR NewswireNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
PR NewswireNVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
PR NewswireMarch 25, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO
PR NewswireShareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
PR NewswireNVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireNVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireNovo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
PR NewswireNVO INVESTOR ALERT: Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireNovo Nordisk launches national Wegovy® campaign, Power of Wegovy®
PR NewswireWegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk conducts a two-for-one stock split
GlobeNewswireNovo Nordisk A/S - share repurchase programme
PR NewswireCanadian Investment Regulatory Organization Trading Halt - NVO.WT
PR NewswireCanadian Investment Regulatory Organization Trading Halt - NVO.WT
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
MyDividendsNovo Nordisk erhöht die Zwischendividende
GlobeNewswireNovo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
GlobeNewswireNovo Nordisk's sales increased by 29% in Danish kroner and by 30% at constant exchange rates to DKK 107.7 billion in the first six months of 2023
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Wer­bung

Novo Nordisk (spons. ADRs) News

Novo Nordisk (spons. ADRs) News: auf dieser Seite finden Sie alle Novo Nordisk (spons. ADRs) News und Nachrichten zur Novo Nordisk (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.